Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-a43f6802b7bc837851c3ee6d33acffd1"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-a43f6802b7bc837851c3ee6d33acffd1"/>
<resource>
<Composition>
<id value="composition-en-a43f6802b7bc837851c3ee6d33acffd1"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-a43f6802b7bc837851c3ee6d33acffd1"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-a43f6802b7bc837851c3ee6d33acffd1</b></p><a name="composition-en-a43f6802b7bc837851c3ee6d33acffd1"> </a><a name="hccomposition-en-a43f6802b7bc837851c3ee6d33acffd1"> </a><a name="composition-en-a43f6802b7bc837851c3ee6d33acffd1-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1696/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - sorafenib</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1696/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpa43f6802b7bc837851c3ee6d33acffd1"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - sorafenib"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Sorafenib Accord is and what it is used for</li><li>What you need to know before you take Sorafenib Accord</li><li>How to take Sorafenib Accord</li><li>Possible side effects</li><li>How to store Sorafenib Accord</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What sorafenib is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What sorafenib is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Sorafenib Accord is used to treat liver cancer (hepatocellular carcinoma). Sorafenib Accord is also used to treat kidney cancer (advanced renal cell carcinoma) at an advanced stage when standard therapy has not helped to stop your disease or is considered unsuitable.</p><p>Sorafenib Accord is a so-called multikinase inhibitor. It works by slowing down the rate of growth of cancer cells and cutting off the blood supply that keeps cancer cells growing.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take sorafenib"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take sorafenib"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Sorafenib Accord</p><ul><li>If you are allergic to sorafenib or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions Talk to your doctor or pharmacist before taking Sorafenib Accord.</p><p>Take special care with Sorafenib Accord</p><ul><li>If you experience skin problems. Sorafenib Accord can cause rashes and skin reactions, especially on the hands and feet. These can usually be treated by your doctor. If not, your doctor may interrupt treatment or stop it altogether.</li><li>If you have high blood pressure. Sorafenib Accord can raise blood pressure, and your doctor will usually monitor your blood pressure and may give you a medicine to treat your high blood pressure.</li><li>If you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall.</li><li>If you have diabetes. Blood sugar levels in diabetic patients should be checked regularly in order to assess if anti-diabetic medicine s dosage needs to be adjusted to minimize the risk of low blood sugar.</li><li>If you get any bleeding problems, or are taking warfarin or phenprocoumon. Treatment with Sorafenib Accord may lead to a higher risk of bleeding. If you are taking warfarin or phenprocoumon, medicines which thin the blood to prevent blood clots, there may be a greater risk of bleeding.</li><li>If you get chest pain or heart problems. Your doctor may decide to interrupt treatment or stop it altogether.</li><li>If you have a heart disorder, such as an abnormal electrical signal called "prolongation of the QT interval".</li><li>If you are going to have surgery, or if you had an operation recently. Sorafenib Accord might affect the way your wounds heal. You will usually be taken off Sorafenib Accord if you are having an operation. Your doctor will decide when to start with Sorafenib Accord again.</li><li>If you are taking irinotecan or are given docetaxel, which are also medicines for cancer. Sorafenib Accord may increase the effects and, in particular, the side effects of these medicines.</li><li>If you are taking Neomycin or other antibiotics. The effect of Sorafenib Accord may be decreased.</li><li>If you have severe liver impairment. You may experience more severe side effects when taking this medicine.</li><li>If you have poor kidney function. Your doctor will monitor your fluid and electrolyte balance.</li><li>Fertility. Sorafenib Accord may reduce fertility in both men and women. If you are concerned, talk to a doctor.</li><li>Holes in the gut wall (gastrointestinal perforation) may occur during treatment (see section 4: Possible Side Effects). In this case your doctor will interrupt the treatment.</li><li>If you have thyroid cancer. Your doctor will monitor blood calcium and thyroid hormone levels.</li><li>If you experience the following symptoms, contact your doctor immediately as this can be a life-threatening condition: nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness. These may be caused by a group of metabolic complications that can occur during treatment of cancer that are caused by the break-down products of dying cancer cells (tumour lysis syndrome (TLS)) and can lead to changes in kidney function and acute renal failure (see also section 4: Possible side effects).</li></ul><p>Tell your doctor if any of these affect you. You may need treatment for them, or your doctor may decide to change your dose of Sorafenib Accord, or stop treatment altogether (see also section 4: Possible side effects).</p><p>Children and adolescents Children and adolescents have not yet been tested with sorafenib.</p><p>Other medicines and Sorafenib Accord Some medicines may affect Sorafenib Accord, or be affected by it. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:</p><ul><li>Rifampicin, neomycin or other medicines used to treat infections (antibiotics)</li><li>St John s wort, a herbal treatment for depression</li><li>Phenytoin, carbamazepine or phenobarbital, treatments for epilepsy and other conditions</li><li>Dexamethasone, a corticosteroid used for various conditions</li><li>Warfarin or phenprocoumon, anticoagulants used to prevent blood clots</li><li>Doxorubicin, capecitabine, docetaxel, paclitaxel and irinotecan, which are cancer treatments</li><li>Digoxin, a treatment for mild to moderate heart failure</li></ul><p>Pregnancy and breast-feeding Avoid becoming pregnant while being treated with Sorafenib Accord. If you could become pregnant, use adequate contraception during treatment. If you become pregnant while being treated with Sorafenib Accord, immediately tell your doctor who will decide if the treatment should be continued.</p><p>You must not breast-feed your baby during Sorafenib Accord treatment, as this medicine may interfere with the growth and development of your baby.</p><p>Driving and using machines There is no evidence that Sorafenib Accord will affect the ability to drive or to operate machines.</p><p>Sorafenib Accord contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose that is to say essentially sodium free .</p></div>
</text>
</section>
<section>
<title value="3. How to take sorafenib"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take sorafenib"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The recommended dose of Sorafenib Accord in adults is 2x200 mg tablets, twice daily. This is equivalent to a daily dose of 800 mg or four tablets a day.</p><p>Swallow Sorafenib Accord tablets with a glass of water, either without food or with a low-fat or moderate fat meal. Do not take this medicine with high fat meals, as this may make Sorafenib Accord less effective. If you intend to have a high fat meal, take the tablets at least 1 hour before or 2 hours after the meal. Always take this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure.</p><p>It is important to take this medicine at about the same times each day, so that there is a steady amount in the bloodstream.</p><p>You will usually carry on taking this medicine as long as you are getting clinical benefits, and not suffering unacceptable side effects.</p><p>If you take more Sorafenib Accord than you should Tell your doctor straight away if you (or anyone else) have taken more than your prescribed dose. Taking too much Sorafenib Accord makes side effects more likely or more severe, especially diarrhoea and skin reactions. Your doctor may tell you to stop taking this medicine.</p><p>If you forget to take Sorafenib Accord If you have missed a dose, take it as soon as you remember. If it is nearly time for the next dose, forget about the missed one and carry on as normal. Do not take a double dose to make up for forgotten dose.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects although not everybody gets them. This medicine may also affect the results of some blood tests.</p><p>Very common side effects: (may affect more than 1 in 10 people)</p><ul><li>diarrhoea</li><li>feeling sick (nausea)</li><li>feeling weak or tired (fatigue)</li><li>pain (including mouth pain, abdominal pain, headache, bone pain, tumour pain)</li><li>hair loss (alopecia)</li><li>flushed or painful palms or soles (hand foot skin reaction)</li><li>itching or rash</li><li>throwing up (vomiting)</li><li>bleeding (including bleeding in the brain, gut wall and respiratory tract; haemorrhage)</li><li>high blood pressure, or increases in blood pressure (hypertension)</li><li>infections</li><li>loss of appetite (anorexia)</li><li>constipation</li><li>joint pain (arthralgia)</li><li>fever</li><li>weight loss</li><li>dry skin</li></ul><p>Common side effects: (may affect up to 1 in 10 people)</p><ul><li>flu-like illness</li><li>indigestion (dyspepsia)</li><li>difficulty swallowing (dysphagia)</li><li>inflamed or dry mouth, tongue pain (stomatitis and mucosal inflammation)</li><li>low calcium levels in the blood (hypocalcaemia)</li><li>low potassium levels in the blood (hypokalaemia)</li><li>low blood sugar level (hypoglycaemia)</li><li>muscle pain (myalgia)</li><li>disturbed sensations in fingers and toes, including tingling or numbness (peripheral sensory neuropathy)</li><li>depression</li><li>erection problems (impotence)</li><li>altered voice (dysphonia)</li><li>acne</li><li>inflamed, dry or scaly skin that sheds (dermatitis, skin desquamation)</li><li>heart failure</li><li>heart attack (myocardial infarction) or chest pain</li><li>tinnitus (ringing sound in the ear)</li><li>kidney failure</li><li>abnormally high levels of protein in the urine (proteinuria)</li><li>general weakness or loss of strength (asthenia)</li><li>decrease in the number of white blood cells (leucopenia and neutropenia)</li><li>decrease in the number of red blood cells (anaemia)</li><li>low number of platelets in the blood (thrombocytopenia)</li><li>inflammation of hair follicles (folliculitis)</li><li>underactive thyroid gland (hypothyroidism)</li><li>low sodium levels in the blood (hyponatraemia)</li><li>distortion of the sense of taste (dysgeusia)</li><li>red in the face and often other areas of the skin (flushing)</li><li>runny nose (rhinorrhoea)</li><li>heartburn (gastro oesophageal reflux disease)</li><li>skin cancer (keratoacanthomas/squamous cell cancer of the skin)</li><li>a thickening of the outer layer of the skin (hyperkeratosis)</li><li>a sudden, involuntary contraction of a muscle (muscle spasms)</li></ul><p>Uncommon side effects: (may affect up to 1 in 100 people)</p><ul><li>inflamed stomach lining (gastritis)</li><li>pain in the tummy (abdomen) caused by pancreatitis, inflammation of the gall bladder and/or bile ducts</li><li>yellow skin or eyes (jaundice) caused by high levels of bile pigments (hyperbilirubinaemia)</li><li>allergic like reactions (including skin reactions and hives)</li><li>dehydration</li><li>enlarged breasts (gynaecomastia)</li><li>breathing difficulty (lung disease)</li><li>eczema</li><li>overactive thyroid gland (hyperthyroidism)</li><li>multiple skin eruptions (erythema multiforme)</li><li>abnormally high blood pressure</li><li>holes in the gut wall (gastrointestinal perforation)</li><li>reversible swelling in the rear part of the brain that can be associated with headache, altered consciousness, fits and visual symptoms including visual loss (reversible posterior leukoencephalopathy)</li><li>a sudden, severe allergic reaction (anaphylactic reaction)</li></ul><p>Rare side effects: may affect up to 1 in 1,000 people</p><ul><li>allergic reaction with swelling of the skin (e. g. face, tongue) that may cause difficulty in breathing or swallowing (angioedema)</li><li>abnormal heart rhythm (QT prolongation)</li><li>inflammation of the liver, which may lead to nausea, vomiting, abdominal pain, and jaundice (drug induced hepatitis)</li><li>a sunburn-like rash that may occur on skin that has previously been exposed to radiotherapy and can be severe (radiation recall dermatitis)</li><li>serious reactions of the skin and/or mucous membranes which may include painful blisters and fever, including extensive detachment of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis)</li><li>abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis)</li><li>damage of the kidney causing them to leak large amounts of protein (nephrotic syndrome)</li><li>inflammation of the vessels in the skin which may result in rash (leucocytoclastic vasculitis)</li></ul><p>Not known side effects: frequency cannot be estimated from the available data</p><ul><li>impaired brain function that can be associated with e.g. drowsiness, behavioural changes, or confusion (encephalopathy)</li><li>an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).</li><li>nausea, shortness of breath, irregular heartbeat, muscular cramps, seizure, clouding of urine and tiredness (Tumour lysis syndrome (TLS)) (see section 2).</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store sorafenib"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store sorafenib"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage condition.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Sorafenib Accord contains</p><ul><li>The active substance is sorafenib. Each film-coated tablet contains 200 mg sorafenib (as tosilate).</li><li>The other ingredients are: Tablet core: croscarmellose sodium, cellulose, microcrystalline, hypromellose, sodium laurilsulfate, magnesium stearate. See section 2 Sorafenib Accord contains sodium .</li></ul><p>Tablet coating: hypromellose (E464), macrogol (E1521), titanium dioxide (E171), ferric oxide red (E172).</p><p>What Sorafenib Accord looks like and contents of the pack</p><p>Sorafenib Accord 200 mg film-coated tablets are red, round, biconvex, bevel-edged, 12.0 mm in diameter, debossed with "H1" on one side and plain on the other side.</p><p>Aluminium-Aluminium perforated unit dose blisters in pack size of 112x1 film-coated tablets in a carton.</p><p>Marketing Authorisation Holder Accord Healthcare S.L.U. World Trade Center, Moll de Barcelona, s/n Edifici Est, 6a Planta 08039 Barcelona Spain</p><p>Manufacturer Accord Healthcare Polska Sp. z.o.o. ul.Lutomierska 95-200, Pabianice Poland</p><p>Pharmadox Healthcare Limited KW20A Kordin Industrial Estate Paola PLA 3Malta</p><p>Accord Healthcare B.V. Winthontlaan 200,<br/>3526 KV Utrecht<br/>The Netherlands</p><p>This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpa43f6802b7bc837851c3ee6d33acffd1"/>
<resource>
<MedicinalProductDefinition>
<id value="mpa43f6802b7bc837851c3ee6d33acffd1"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpa43f6802b7bc837851c3ee6d33acffd1"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpa43f6802b7bc837851c3ee6d33acffd1</b></p><a name="mpa43f6802b7bc837851c3ee6d33acffd1"> </a><a name="hcmpa43f6802b7bc837851c3ee6d33acffd1"> </a><a name="mpa43f6802b7bc837851c3ee6d33acffd1-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1696/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Sorafenib Accord 200 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1696/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Sorafenib Accord 200 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
